Review ArticleOpen Access

Novel Therapy of the Carcinoid Syndrome Related Diarrhea

Volume 7 - Issue 3

**Marina Ruxandra Oțelea¹, Sabina Antoniu², Emma Gheorghe³, Mădălina Iliescu⁴, Ioan Anton Arghir⁵, Agripina Rașcu⁶ and Viorel Scripcariu⁷**

Author Information Open or Close
- ¹Assistant Professor, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- ²Associate Professor, Grigore T Popa University of Medicine and Pharmacy, Romania
- ³Associate Professor, Ovidius University of Constanța, Romania
- ⁴Assistant Professor, Medicine Faculty, Ovidius University of Constanț a, Romania
- ⁵Medical Student, Medicine Faculty, Ovidius University of Constanț a, Romania
- ⁶Professor, Carol Davila University of Medicine and Pharmacy Bucharest, Romania
- ⁷Professor, Grigore T Popa University of Medicine and Pharmacy Iasi, Romania
*Corresponding author: Marina Ruxandra Oțelea, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

*Corresponding author: Emma Gheorghe, Associate Professor, Ovidius University of Constanța, Romania

Received: July 24, 2018; Published: August 01, 2018

DOI: 10.26717/BJSTR.2018.07.001517

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Carcinoid syndrome, characterized by symptoms such as diarrhea, flushing or wheezing, is caused by an excessive production of serotonin. Diarrhea and excessive bowel movement negatively affects the quality of life of these patients. Somatostatin analogues are efficacious but cannot optimally control symptoms. A review of clinical efficacy data in supporting the therapeutic indication for orphan drug designation is presented focused on the new approved drug, telotristat ethyl, an inhibitor of the tryptophan hydroxylase type I enzyme involved in the synthesis of serotonin. By depleting serotonin in the gastrointestinal tract, telotristat ethyl interrupts the pathological chain process of the diarrhea and demonstrated efficacy in patients with carcinoid syndrome.

Keywords: Diarrhea; Telotristat Ethyl; Carcinoid Syndrome

Keywords: TPH: Tryptophan Hydroxylase; SERT: Serotonin-Selective Reuptake Transporter; FDA: Food and Drug Administration; DLT: Dose Limiting Toxicity; SA: Somatostatin Analogues